GlassScriptPhysician profile
Julie Ann Bryan
NPI 1063496644
$3,745.67
in general payments reported to CMS, 2019-2025
26 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $138 · 2021: $333 · 2022: $485 · 2023: $640 · 2024: $122 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.01 | 2019-2025 | Vraylar, Dalvance, Teflaro |
| Amgen INC. | $479.84 | 2019-2025 | Repatha, Evenity |
| Novo Nordisk INC | $426.59 | 2019 | |
| Lilly USA, LLC | $403.07 | 2019-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $254.39 | 2021-2023 | |
| Axsome Therapeutics, INC. | $226.08 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $200.43 | 2019-2025 | Airsupra |
| Pfizer INC. | $177.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $146.18 | 2019-2023 | Arexvy |
| Astellas Pharma US INC | $145.63 | 2020-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $123.14 | 2019 | |
| Dynavax Technologies Corporation | $109.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.38 | 2019 | |
| Amarin Pharma, INC. | $43.29 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $40.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.83 | 2019-2020 | |
| Dexcom, INC. | $25.54 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $25.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $19.53 | 2019 | |
| Merck Sharp & Dohme LLC | $16.76 | 2025 | Gardasil 9, Capvaxive |
| Daiichi Sankyo INC. | $16.64 | 2019 | |
| Alkermes, INC. | $14.73 | 2019 | |
| Radius Health, INC. | $13.14 | 2019 | |
| Mylan Specialty L.P. | $12.33 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.